BioLegend has announced it has acquired Covance's antibody products business unit, located in Dedham, Massachusetts. This unit includes R&D and manufacturing of antibodies and research reagents for Neuroscience, Immunopathology, Cell Biology, Epitope Tags, and Immunohistochemistry (IHC) Detection. These products, including In Vitro Diagnostic (IVD) antibodies for IHC, complement and enhance the current selection of BioLegend research reagents. Covance antibody customers can expect the same superior customer support and exceptional value with these products as existing BioLegend customers.
As neuroinflammation and neurodegeneration become increasingly important topics, BioLegend is committed to the advancement of discovery in neuroscience. With the addition of a world-class R&D team and over 600 antibody products for emerging and important targets in this field, BioLegend is positioned to become a leader in neuroscience and immunology research.
“The addition of Neuroscience and IHC antibody tools to our catalog means accelerated discovery for our current and new customers. We also hope to bring our well-known quality, support, and value in the Immunology community to Neuroscience researchers world-wide,” said Gene Lay, Founder, President and CEO, BioLegend.
To learn more about the changes and how they may affect you, read the Q and A section below.
Q: Why is BioLegend entering this agreement with Covance?
A: BioLegend is seeking to expand our product portfolio into new areas including Neuroscience, Immunopathology, and IHC reagents. Covance Antibodies not only expand BioLegend's catalog, but also complement current BioLegend offerings.
Q: Why is Covance selling the Covance Antibody group to BioLegend?
A: The goal of divesting the group was to place it in an organization that better aligns with the focus of the group, would value and grow the group to increase the business. We believe that BioLegend's commitment to providing researchers with the most comprehensive and cutting-edge high quality reagents for life science research, strong background in research tools, and aggressive product development program positions the Antibodies Products group for increased commercial growth and greater career opportunities for employees.
Q: Will management of the Antibodies Product group remain the same?
A: Yes, the entire staff of the Antibodies Product group remains the same.
Q: I get a great discount for my BioLegend products, can I apply this to former Covance Antibody products?
A: We are always looking to provide our products at an outstanding value. At the moment, we are not extending any current BioLegend discounts to former Covance products. We are working to realize additional process efficiencies through our integration efforts and will, as always, look to share the benefits of such with our customers.